Summary

Results of a phase 3 study indicate that adjunctive treatment with brivaracetam can significantly reduce the frequency of partial-onset seizures previously refractory to pharmacotherapy and improve responder rates. Patients receiving brivaracetam also had a higher rate of seizure freedom during treatment compared with those receiving placebo. Brivaracetam is safe and well tolerated.